摘要
背景:肾细胞癌(RCC)占所有成人恶性肿瘤的2%,病死率高达40%。过去六十年来,农村信用合作社一直在增长2%。已经做了许多工作来发现疾病的发病机理,血管发生的作用一直是与血管内皮生长因子(VEGF)及其下游效应物连同雷帕霉素(mTOR)介导的信号转导途径的哺乳动物靶标的复发分子。 目的:本次审查将讨论该疾病关键生物标志物的相关抑制剂,希望为改善RCC发病率和死亡率的新型治疗铺平道路。 结果与结论:目前,晚期RCC的治疗包括以下一项或多项:部分或根治性肾切除术,全身治疗,免疫治疗和靶向治疗。仍然耐药性仍然是许多批准的药物和接受临床试验的药物的挑战。然而,包括靶向治疗方法已经改善了与单纯手术相比,高级RCC治疗的成功率以及传统化学疗法对这种相对耐药性疾病的成功率。在个性化医学的时代,利用多药理学方法的研究可以提高药物治疗RCC的疗效。.
关键词: 雷帕霉素的哺乳动物靶标,个性化药物,血管生成,肾细胞癌,血管内皮生长因子,多靶点方法。
Current Drug Targets
Title:Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review
Volume: 18 Issue: 10
关键词: 雷帕霉素的哺乳动物靶标,个性化药物,血管生成,肾细胞癌,血管内皮生长因子,多靶点方法。
摘要: Background: Renal cell carcinoma (RCC) accounts for 2% of all adult malignancies and is associated with a case fatality rate as high as 40%. RCC has been on the rise for the last 6 decades at a steady increase of 2% per annum. Much work has been done to uncover the pathogenesis of the disease and the role of angiogenesis has been a recurrent denominator connected to vascular endothelial growth factor (VEGF) and its downstream effectors along with the mammalian target of rapamycin (mTOR) mediated signal transduction pathway.
Objective: This review will discuss relevant inhibitors of key biomarkers to the disease in hopes of paving the way for novel treatments geared towards improving RCC morbidity and mortality rates. Results and Conclusion: Currently, treatment of advanced RCC includes one or more of the following: partial or radical nephrectomy, systemic therapy, immunotherapy and targeted therapy. Still drug resistance continues to be a challenge to many of the approved drugs and those undergoing clinical trials. However, the inclusion of targeted therapies has improved advanced RCC treatment success rates over that of surgery alone, and over that of the use of traditional chemotherapy for this relatively chemo-resistant disease. In an era of personalized medicine, research utilizing a polypharmacology approach could enhance efficacy of drug leads to treating RCC.Export Options
About this article
Cite this article as:
Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450117666160502152518
DOI https://dx.doi.org/10.2174/1389450117666160502152518 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry Molecularly Targeted Therapy in Breast Cancer: The New Generation
Recent Patents on Anti-Cancer Drug Discovery Health Benefits, Therapeutic Applications, and Recent Advances of Cirsilineol in the Medicine: Potential Bioactive Natural Flavonoids of Genus <i>Artemisia</i>
Endocrine, Metabolic & Immune Disorders - Drug Targets Computational Simulations of the Immune System for Personalized Medicine: State of the Art and Challenges
Current Pharmacogenomics and Personalized Medicine Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials
Anti-Cancer Agents in Medicinal Chemistry Carcinogenesis and Diabetic Wound Healing: Evidences of Parallelism
Current Diabetes Reviews Transcatheter Embolization Therapy in Liver Cancer
Recent Patents on Medical Imaging Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry Drug Metabolism and Pharmacokinetics of Nanodrugs from Chinese Medicines and Natural Products
Current Drug Metabolism The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Regulation of HIPK Proteins by MicroRNAs
MicroRNA Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Emerging In Vitro Tools to Evaluate Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions
Current Drug Discovery Technologies Laparoscopic Reconstructive Surgery in Pediatric Urology: An Overview of Current Options
Current Pediatric Reviews The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry